Breaking Down Sunflower Pharmaceutical Group Co.,Ltd Financial Health: Key Insights for Investors

Investors scrutinizing Sunflower Pharmaceutical Group Co., Ltd. (002737.SZ) will find a mixed financial picture: in Q1 2024 operating income slid to 1.518 billion yuan (a -14.01% year‑over‑year drop) after the company posted 5.70 billion yuan in operating income for 2023 (up 11.89% vs. 2022), yet revenues across the last twelve months as of Sept 30, 2025 fell to 2.09 billion yuan (a -52.75% YOY decline) as higher raw material costs and reduced production scale squeezed top line and margins; profitability trends echo the pressure-Q1 2024 net profit was 255 million yuan (down 37.17% YOY), 2023 net profit attributable to shareholders reached 1.119 billion yuan (up 29.05% YOY), while the company forecasts H1 2025 net profit attributable to shareholders of 70-85 million yuan (a year‑over‑year decline of 82.52%-85.61%), and net finance costs rose from ~7.4 million to ~7.8 million yuan year‑on‑year in H1 2025 due mainly to lower net FX gains; on the capital markets and valuation front Sunflower carries a market capitalization of 8.85 billion yuan with enterprise value of 6.87 billion yuan, 584 million shares outstanding (down 4.05% YoY), a low beta of 0.25 and a 12‑month stock decline of 28.48%, while valuation multiples show a premium stance (P/S 4.18, P/B 2.08, P/FCF 38.41, P/OCF 28.23); reported risks include raw material price volatility, regulatory shifts, FX exposure and competitive pressures, even as management projects operating income of 6.370 billion in 2024 rising to 8.222 billion in 2026 and targets net profit growth to 1.482 billion by 2026 through portfolio expansion, R&D and its '6th Five‑Year Plan' focused on scaling flagship products and building product clusters.

Sunflower Pharmaceutical Group Co.,Ltd (002737.SZ) - Revenue Analysis

• Q1 2024 operating income: ¥1.518 billion - down 14.01% vs Q1 2023.
• Full-year 2023 operating income: ¥5.70 billion - up 11.89% vs 2022.
• LTM (as of 30 Sep 2025) revenue: ¥2.09 billion - down 52.75% YoY.
• Management guidance for H1 2025 net profit attributable to shareholders: ¥70-85 million - implying a YoY decline of 82.52%-85.61%.

Primary drivers of the revenue contraction:

• Significantly higher raw material costs compressing margins and forcing price/volume adjustments.
• Decreased production scale leading to lower shipment volumes and utilization.
• Rising operating expenses in 2025 further eroding revenue-to-profit conversion.

For context on corporate history, ownership and business model, see: Sunflower Pharmaceutical Group Co.,Ltd: History, Ownership, Mission, How It Works & Makes Money

Sunflower Pharmaceutical Group Co.,Ltd (002737.SZ) - Profitability Metrics

Key profitability figures and near-term guidance for Sunflower Pharmaceutical Group highlight a company facing margin pressure despite a strong 2023 baseline.

• Q1 2024 net profit: 255 million yuan (↓37.17% vs Q1 2023).
• FY 2023 net profit attributable to shareholders: 1.119 billion yuan (↑29.05% vs 2022).
• H1 2025 guidance: expected net profit attributable to shareholders 70-85 million yuan (year‑on‑year decrease of 82.52%-85.61%).
• 2023 dividend proposal: 15.00 yuan (including tax) per 10 shares.

• Primary drivers of recent profit decline:
  • Rising raw material costs pushing down net profit margin.
  • Increased operating costs (production, logistics, SG&A).
  • Decreased production scale reducing operating leverage.
• Investor considerations:
  • Volatility in commodity/raw material pricing materially affects margins.
  • Management's ability to restore scale and contain operating costs is key to near-term recovery.
  • Generous 2023 dividend supports shareholder returns despite short‑term earnings pressure.

For corporate background and context on strategy and ownership, see: Sunflower Pharmaceutical Group Co.,Ltd: History, Ownership, Mission, How It Works & Makes Money

Sunflower Pharmaceutical Group Co.,Ltd (002737.SZ) - Debt vs. Equity Structure

• Market capitalization: ¥8.85 billion (as of 2025-12-17)
• Enterprise value (EV): ¥6.87 billion (as of 2025-12-17)
• Implied net cash (EV - Market Cap): ¥-1.98 billion → implies roughly ¥1.98 billion net cash on the balance sheet
• Shares outstanding: 584 million (down 4.05% year-over-year)
• Beta: 0.25 (low volatility relative to the market)
• 12-month stock performance: -28.48%
• Debt-to-equity ratio: not specified in available sources

• Net cash implied by EV < market cap suggests limited financial leverage and potential balance-sheet flexibility.
• Low beta (0.25) indicates the equity has historically shown muted sensitivity to market swings-useful for risk allocation decisions.
• Decline in shares outstanding (-4.05%) could reflect buybacks, cancellations, or capital structure adjustments-review filings for details.
• Absence of a disclosed debt-to-equity ratio requires direct review of latest financial statements to confirm on‑balance-sheet debt levels and off‑balance obligations.

Sunflower Pharmaceutical Group Co.,Ltd (002737.SZ) Liquidity and Solvency

Key liquidity and solvency metrics for Sunflower Pharmaceutical Group Co.,Ltd (002737.SZ) are limited in publicly available sources. Where figures are disclosed, they point to a modest increase in financing costs driven by foreign exchange effects.

• Current ratio: Not disclosed in available sources.
• Quick ratio: Not disclosed in available sources.
• Cash flow from operations: Not disclosed in available sources.
• Interest coverage ratio: Not disclosed in available sources.
• Solvency position (overall leverage, debt-to-equity metrics): Not disclosed in available sources.

Investors seeking deeper historical, ownership and business-model context can consult: Sunflower Pharmaceutical Group Co.,Ltd: History, Ownership, Mission, How It Works & Makes Money

Sunflower Pharmaceutical Group Co.,Ltd (002737.SZ) - Valuation Analysis

• Relative premium: Across revenue, book and cash-flow multiples the company trades above typical pharmaceutical peer medians, indicating scarce downside perceived by investors or anticipated above-average growth.
• Cash-flow scrutiny: P/FCF of 38.41 and P/OCF of 28.23 warrant close monitoring of FCF conversion, capex cadence and working-capital swings to validate current pricing.
• Asset backing: P/TBV at 2.41 shows intangibles and ongoing business value are being priced materially above tangible assets - important for capital-intensive or IP-driven pharma businesses.
• Margin of safety: Investors seeking valuation cushion should compare these multiples to peer percentiles, sensitivity-check FCF forecasts, and stress-test revenue decline scenarios.

• Growth scenario: If revenue growth sustains mid-to-high single digits with stable margins, P/S 4.18 could be supported by improving ROIC and margin expansion.
• Cash conversion risk: A 10-20% decline in FCF versus consensus would materially lift P/FCF, exposing valuation vulnerability given the 38.41 starting point.
• Balance-sheet buffer: With P/B at 2.08 and P/TBV at 2.41, downside recoveries would depend on either rapid margin recovery or value realization of intangible assets.

Sunflower Pharmaceutical Group Co.,Ltd (002737.SZ) Risk Factors

Sunflower Pharmaceutical Group Co.,Ltd (002737.SZ) faces a spectrum of operational, market and regulatory risks that can materially affect its financial health. Investors should weigh these risks alongside historical performance and growth prospects. The most salient risk categories are outlined below.

• Raw material cost volatility: the company sources active pharmaceutical ingredients (APIs) and excipients whose prices can swing with global commodity cycles and supply-chain disruptions. In FY2023 management noted higher input costs that compressed gross margins.
• Regulatory change risk: shifts in China's drug pricing, GMP/quality standards, and approval pathways (including NRDL listings and centralized procurement) can alter revenue timing and product pricing power.
• Competitive pressure: competition from domestic generics producers and multinational pharmaceutical firms can pressure pricing, market share and required R&D investment to sustain differentiation.
• Foreign exchange exposure: although primarily RMB-denominated, import of APIs and raw materials priced in USD/EUR and export sales expose the company to FX swings.
• R&D and commercialization risk: pipelines require successful clinical development, regulatory approvals and market uptake. Failures or delays can reduce expected future cash flows and impair asset values.
• Product quality and recall risk: manufacturing non-conformances, batch failures or post-market safety issues could prompt recalls, regulatory fines and reputational damage.

Quantifying key exposures and outcomes helps frame potential financial impacts. Below is a concise snapshot of FY2023-FY2024 metrics and sensitivity indicators reported or disclosed in public filings and management commentary.

Risk drivers and possible investor actions:

• Raw material fluctuations: monitor management disclosures on hedging, long-term supplier contracts and pass-through pricing clauses; sensitivity: a 10% API cost rise could reduce gross margin by ~3-4 percentage points.
• Regulatory shifts: track NRDL negotiation outcomes, GMP inspection findings and changes in pricing policy-these can affect revenue recognition and unit economics quickly.
• Competition: watch product launch timelines, patent expiries and pricing trends in core therapeutic areas; market-share erosion could pressure top-line CAGR assumptions.
• FX movements: assess treasury policy-use of forwards/forwards contracts or natural hedges; unmanaged FX risk can turn moderate foreign purchases into significant margin headwinds.
• R&D success: evaluate stage-gate milestones and capital allocation to new molecules vs. lifecycle management; high failure rates necessitate contingency valuation models.
• Quality controls: review inspection history, CAPA (corrective and preventive actions) spend and recall provisions-material recalls can create multi-period earnings shocks.

For historical context on corporate structure and strategic direction, see: Sunflower Pharmaceutical Group Co.,Ltd: History, Ownership, Mission, How It Works & Makes Money

Sunflower Pharmaceutical Group Co.,Ltd (002737.SZ) - Growth Opportunities

• Operating income targets: 6.370 billion yuan (2024), 7.229 billion yuan (2025), 8.222 billion yuan (2026).
• Net profit targets: 1.186 billion yuan (2024), 1.318 billion yuan (2025), 1.482 billion yuan (2026).
• Strategic program: implementation of a '6th Five-Year Plan' to accelerate growth, build flagship 'gold' products, and expand gold single product clusters.
• Product focus: expansion of exclusive varieties and entries into the national essential drug catalogue to secure steady market demand and pricing power.
• R&D emphasis: active pursuit of research and development to meet future development needs and support lifecycle management of core products.

• Implied margins: based on stated targets, net profit margin is approximately 18%-19% across 2024-2026, signaling management expects margin stability while scaling revenue.
• Product-cluster strategy: concentrating investment into 'large gold products' and gold single product clusters to generate higher, recurring revenue streams and leverage existing commercial channels.
• Catalogue and exclusivity strategy: aiming for inclusion in the national essential drug catalogue and expanding exclusive varieties to secure reimbursement coverage and defend pricing.
• R&D pipeline and capex: continued R&D spend is prioritized to underpin next-generation launches and convert pipeline assets into product-level growth drivers.